Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|July 19, 2017
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapyMichael A Cannarile, Martin Weisser, Wolfgang Jacob, et al.
Cancer Chemotherapy and Pharmacology|May 13, 2017
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumabGeorgina Meneses-Lorente, Christine McIntyre, Joy C Hsu, et al.
Plos One|May 12, 2017
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancerDenis Collins, Wolfgang Jacob, Juan Miguel Cejalvo, et al.
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusionHye Sook Kim, Ji-Youn Han, Dong Hoon Shin, et al.
Oncogene|August 29, 2003
The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent mannerAnnika Elsässer, Michael Franzen, Alexander Kohlmann, et al.
Molecular Cancer Therapeutics|April 15, 2018
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination TherapyAnnie Moisan, Francesca Michielin, Wolfgang Jacob, et al.
Methods (San Diego, Calif.)|July 17, 2012
Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assaysSabine Lohmann, Andrea Herold, Tobias Bergauer, et al.
Clinical Pharmacology and Therapeutics|June 17, 2026
Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple MyelomaThomas E Kraft, Estelle Marrer-Berger, Sara Belli, et al.
Blood Advances|December 23, 2021
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphomaAnn-Marie E Bröske, Koorosh Korfi, Anton Belousov, et al.
ESMO Open|August 20, 2019
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancerJuan-Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas Kanonnikoff, et al.
Pageof 4